

**Bronwen Elizabeth Shaw  
MBChB, PhD**

**Current position**

Sep 2014-current **Professor of Medicine**  
**Associate Scientific Director**  
CIBMTR  
Froedtert & the Medical College of Wisconsin

**Employment History**

April 2007-July 2014 **Clinical Senior Lecturer and Honorary Consultant in Blood and Marrow Transplantation (3 days/week)**  
Institute of Cancer Research/ Royal Marsden NHS Foundation Trust

**Chief Medical Officer and Head of the Clinical Research Group, Anthony Nolan (2 days/week)**  
Anthony Nolan

Dec/Jan 2006/07 **Locum Consultant in Lymphoma and General Haematology**  
Nottingham City Hospital

Oct/Nov 2006 **Locum Consultant in Lymphoma and General Haematology**  
St Marys Hospital

Aug 2004 – Aug 2006 **SpR in haematology with a specialist interest in Blood and Bone Marrow Transplantation**  
Nottingham City Hospital  
Professor Nigel Russell, Jennifer Byrne, Emma Das-Gupta, Andy Haynes, Andrew McMillan

Jan 2001 - Jun 2004 **Medical Officer at Anthony Nolan**

July 2000- July 2004 **Research Fellow at the Anthony Nolan Research Institute for four years during which time I obtained my PhD (funded by the ANT) from the University of London**  
“Understanding the immunogenetic and clinical factors which influence the outcome of haematopoietic stem cell transplantation using unrelated donors”  
Supervisors: J A Madrigal, S G E Marsh

Dec 1997- June 2000 **Haematology Specialist Registrar, North West Thames**

Ealing Hospital, Dr. Hegde  
Royal Free Hospital, Professor H. Grant Prentice  
Northwick Park Hospital, Dr Reid

Apr 1995 - Nov 1997

**Medical SHO Rotation**  
London

1994

**House Officer**  
Groote Schuur University Hospital, Cape Town, South Africa

### **Education**

November 2004 PhD in Clinical Sciences from University College London  
"Understanding the immunogenetic and clinical factors which influence the outcome of haematopoietic stem cell transplantation using unrelated donors"

September 2005 Membership of the Royal College of Pathologist (London) Part II

June 2000 Diplomate of the Royal College of Pathologist (London) Part I

July 1997 Membership of the Royal College of Physicians (London) Part II

July 1996 Membership of the Royal College of Physicians (London) Part I

1988 – 1993 MB ChB University of Cape Town, South Africa

### **Funding**

2009/10 Gilead Antifungal Audit (data-manager) £20 000  
2010-2014 HEFCE-Clinical Senior Lecturer Fellowship £250 000  
2010-2012 MD Fellowship in Graft versus Host Disease £75 000  
2012-2015 Immune Reconstitution in Cord Blood Transplantation  
£82,000  
2012 Next 7 steps £15 000

### **Prizes**

2006 BSBMT Scientific day - Best abstract  
2007 EBMT Von Bekkum award – Best abstract

### **Societies and Committees**

#### **Member of the following Societies:**

American Society of Haematology (ASH)  
British Society of Haematology (BSH)  
European Society for Blood and Marrow Transplantation (EBMT)  
British Society for Blood and Marrow Transplantation (BSBMT)  
European Federation of Immunogenetics (EFI)  
World Marrow Donor Association (WMDA)

### **Leadership positions currently held:**

- Member of the NMDP Histocompatibility Advisory Group (September 2014 -)
- Member of the Research Oversight Committee for Genome Quebec: Personalised Cancer Immunotherapy (PI: Perreault) (2013-2017)
- Co-chair of the CIBMTR Donor Health and Safety committee (2012 – )
- Chair of the S(P)EAR committee of the WMDA (2009 -)
- Member of the Donor Standing Committee for the WBMT (2010 - )
- Member of the advisory committee for the 5th and 6th edition of the Fact/JACIE clinical standards (2011-)
- Member of the WHO NOTIFY group for Vigilance and Surveillance (2011-) and Editorial lead for the Living donor group (2011 - )

### **National and International Leadership positions previously held:**

#### **UK:**

- Member of the BSBMT executive board (2011 - 2014)
- Chair of the Clinical Trials Committee of the BSBMT (2012 - 2014 )
- Chair of the BSBMT education group (2012 - 2014)
- Member of the Anthony Nolan medical advisory group (to 2014)
- Member of the UK cord blood working group (to 2014)
- Member of the Medical Advisory Group of the UK strategic Stem cell Forum (2011 – 2014)

#### **International:**

- Program chair of the IDRC, London 2014
- Chair of the Clinical Working Group and board member of the World Marrow Donor Association (July 2008 – July 2014)
- Member of the Editorial Review board for Bone Marrow Transplantation journal (March 2008 – March 2014)
- Member of the Editorial Review board for Frontiers in Alloimmunity and Transplantation (2011 - )
- Faculty of ESH - EBMT Training Course on Haemopoietic Stem Cell Transplantation (2011- 2014)

### **Other activities**

Regular reviewer of meeting abstracts (EBMT, ASH, EHA, BSBMT)

Regular chair for meeting sessions (EBMT, Tandem, EHA, IHWG)

Program committee member for the IDRC (2009-2014)

Regular reviewer of Journal articles (Blood, Haematologica, JCO, Lancet Oncology BMT etc)

## Chapters

- Bronwen E. Shaw**, Alejandro Madrigal. Immunogenetics of allogeneic HSCT. In: ESH-EBMT Handbook on HSCT (6th Edition). Editors: Jane Apperley, Enric Carreras, Eliane Gluckman, Tamas Masszi; 2012.
- Bronwen E Shaw**. HLA matching, compatibility testing and donor selection. In: Haematopoietic Stem Cell Transplantation in Clinical Practice. John Barrett & Jennie Treleaven, ed. London: Churchill Livingstone Elsevier; 2009.
- Bower M, Bowles KM, Brock CS, Dark GG, Fife KM, Galvani DW, Olujohungbe ABK, **Shaw BE**. Haematology and Oncology. In: Medical Masterclass. Second edition. Firth J, ed. London: Royal College of Physicians of London; 2008
- Bronwen Shaw**, Simon O'Connor, Andrew P Haynes. Lymphoproliferative Disorders Including Chronic Lymphocytic Leukaemia. In: ABC of Clinical Haematology 3rd edition. Provan, D, ed. London: Blackwell BMJ Books; 2007
- Bower M, Bowles KM, Dark GG, Galvani DW, **Shaw BE**. Haematology and Oncology. In: Medical Masterclass. Firth J, ed. London: Blackwell Science; 2001

## Publications

1. Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, Askar M, Dehn J, Fernandez Viña M, Gratwohl A, Gupta V, Hanna R, Horowitz MM, Hurley CK, Inamoto Y, Kassim AA, Nishihori T, Mueller C, Oudshoorn M, Petersdorf EW, Prasad V, Robinson J, Saber W, Schultz KR, **Shaw B**, Storek J, Wood WA, Woolfrey AE, Anasetti C. Non-permissive -DPB1 mismatch among otherwise HLA-matched donor-recipient pairs results in increased overall mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation for hematologic malignancies. *Blood*. 2014 Aug 26. pii: blood-2014-05-576041. [Epub ahead of print]
2. Lee F, Luevano M, Veys P, Yong K, Madrigal A, **Shaw BE**, Saudemont A. The Effects of CAMPATH-1H on Cell Viability Do Not Correlate to the CD52 Density on the Cell Surface. *PLoS One*. 2014 Jul 22;9(7):e103254.
3. Fleischhauer K, Fernandez-Viña MA, Wang T, Haagenson M, Battiwalla M, Baxter-Lowe LA, Ciceri F, Dehn J, Gajewski J, Hale GA, Heemskerk MB, Marino SR, McCarthy PL, Miklos D, Oudshoorn M, Pollack MS, Reddy V,

- Senitzer D, **Shaw BE**, Waller EK, Lee SJ, Spellman SR. Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1. *Bone Marrow Transplant*. 2014 Sep;49(9):1176-83
4. Feliu J, Clay J, Raj K, Barber L, Devlia V, **Shaw B**, Pagliuca A, Mufti G. Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies. *Br J Haematol*. 2014 Jun 25. doi: 10.1111/bjh.12992. [Epub ahead of print]
  5. Das-Gupta E, Dignan F, **Shaw B**, Raj K, Malladi R, Gennery A, Bonney D, Taylor P, Scarisbrick J. Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literature. *Bone Marrow Transplant*. 2014 Jun 2. doi: 10.1038/bmt.2014.106. [Epub ahead of print]
  6. Billen A, Madrigal JA, Szydlo RM, **Shaw BE**. Female donors and donors who are lighter than their recipient are less likely to meet the CD34+ cell dose requested for peripheral blood stem cell transplantation. *Transfusion*. 2014 May 27. doi: 10.1111/trf.12720. [Epub ahead of print]
  7. Pulsipher MA, Chitphakdithai P, Logan BR, Navarro WH, Levine JE, Miller JP, **Shaw BE**, O'Donnell PV, Majhail NS, Confer DL. Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. *Blood*. 2014 Jun 5;123(23):3655-63.
  8. Lown RN, Philippe J, Navarro W, van Walraven SM, Philips-Johnson L, Fechter M, Pawson R, Bengtsson M, Beksac M, Field S, Yang H, **Shaw BE**. Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee. *Bone Marrow Transplant*. 2014 Jul;49(7):880-6.
  9. Dignan FL, Aguilar S, Scarisbrick JJ, **Shaw BE**, Potter MN, Cavenagh J, Apperley JF, Fielding AK, Pagliuca A, Raj K, Marks DI, Peniket A, Crawley C, Koh MB, Child FJ. Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD. *Bone Marrow Transplant*. 2014 May;49(5):704-8.
  10. Anthias C, Dignan FL, Morilla R, Morilla A, Ethell ME, Potter MN, **Shaw BE**. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. *Bone Marrow Transplant*.

2014 May;49(5):679-83.

11. Billen A, Madrigal JA, **Shaw BE**. A review of the haematopoietic stem cell donation experience: is there room for improvement? *Bone Marrow Transplant*. 2014 Jun;49(6):729-36.
12. Lown RN, Marsh SG, Switzer GE, Latham KA, Madrigal JA, **Shaw BE**. Ethnicity, length of time on the register and sex predict donor availability at the confirmatory typing stage. *Bone Marrow Transplant*. 2014 Apr;49(4):525-31.
13. Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, Marks DI, Jackson B, Chakupurakal G, Dennis M, Lim Z, Cook G, Carpenter B, Pettitt AR, Mathew S, Connelly-Smith L, Yin JA, Viskaduraki M, Chakraverty R, Orchard K, **Shaw BE**, Byrne JL, Brookes C, Craddock CF, Chaganti S. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. *Bone Marrow Transplant*. 2014 Feb;49(2):280-6.
14. **Shaw BE**, Chapman J, Fechter M, Foeken L, Greinix H, Hwang W, Phillips-Johnson L, Korhonen M, Lindberg B, Navarro WH, Szer J. Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation. *BMT*. 2013 Nov;48(12):1506-9.
15. Lown RN, Tulpule S, Russell NH, Craddock CF, Roest R, Madrigal JA, **Shaw BE**. Subsequent donation requests among 2472 unrelated hematopoietic progenitor cell donors are associated with bone marrow harvest. *Haematologica*. 2013 Dec;98(12):1956-63.
16. **Shaw BE**, Robinson J, Fleischhauer K, Madrigal JA, Marsh SG. Translating the HLA-DPB1 T-cell epitope-matching algorithm into clinical practice. *Bone Marrow Transplant*. 2013 Nov;48(12):1510-2.
17. Medd PG, Peniket AJ, Littlewood TJ, Pearce R, Perry J, Kirkland KE, **Shaw BE**, Potter MN, Craddock CF, Milligan DW, Fielding AK, Marks DI, Cook G. Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study. *Bone Marrow Transplant*. 2013 Jul;48(7):982-7.
18. Dignan FL, Potter MN, Ethell ME, Taylor M, Lewis L, Brennan J, McNamara L, Evans SO, Riley U, Davies FE, Dearden CE, Morgan GJ, **Shaw BE**. High readmission rates are associated with a significant economic burden and poor

- outcome in patients with grade III/IV acute GvHD. Clin Transplant. 2013 Jan-Feb;27(1):E56-63.
19. Dignan FL, Manwani R, Potter MN, Ethell ME, Leonard H, Brennan J, Baker J, **Shaw BE**. A dedicated GvHD clinic may improve the quality of life for allogeneic stem cell transplant survivors. Clin Transplant. 2013 Jan-Feb;27(1):E1-2.
  20. Arrieta-Bolaños E, Madrigal JA, **Shaw BE**. Human leukocyte antigen profiles of latin american populations: differential admixture and its potential impact on hematopoietic stem cell transplantation. Bone Marrow Res.2012;2012:136087.
  21. **Shaw BE**. Allogeneic transplantation: When is a mismatch better than a match? Biol Blood Marrow Transplant. 2013 Jan;19(1):1-2.
  22. Mayor NP, **Shaw BE**, Madrigal JA, Marsh SG. NOD2 Polymorphisms and Their Impact on Haematopoietic Stem Cell Transplant Outcome. Bone Marrow Res. 2012;2012:180391.
  23. Pulsipher MA, Chitphakdithai P, Logan BR, **Shaw BE**, Wingard JR, Lazarus HM, Waller EK, Seftel M, Stroncek DF, Lopez AM, Maharaj D, Hematti P, O'Donnell PV, Loren AW, Leitman SF, Anderlini P, Goldstein SC, Levine JE, Navarro WH, Miller JP, Confer DL. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the NMDP. Blood. 2013 Jan 3;121(1):197-206.
  24. Lown RN, **Shaw BE**. 'First do no harm': where do we stand on unrelated hematopoietic cell donor safety? Expert Rev Hematol. 2012 Jun;5(3):249-52.
  25. Halter JP, van Walraven SM, Worel N, Bengtsson M, Hägglund H, Nicoloso de Faveri G, **Shaw BE**, Schmidt AH, Fechter M, Madrigal A, Szer J, Aljurf MD, Weisdorf D, Horowitz MM, Greinix H, Niederwieser D, Gratwohl A, Kodera Y, Confer D. Allogeneic hematopoietic stem cell donation: standardized assessment of donor outcome data-A WBMT consensus document. Bone Marrow Transplant. 2013 Feb;48(2):220-5.
  26. Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G, Mahendra P, Taylor PC, Shah P, Lightman S, Fortune F, Kibbler C, Andreyev J, Albanese A, Hadzic N, Potter MN, **Shaw BE**; on behalf of the Haematology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow Transplantation. Organ-specific

- management and supportive care in chronic graft-versus-host disease. *Br J Haematol.* 2012 Jul;158(1):62-78.
27. Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, Scarisbrick JJ, Taylor PC, Hadzic N, **Shaw BE**, Potter MN; on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow Transplantation. Diagnosis and management of acute graft-versus-host disease. *Br J Haematol.* 2012 Jul;158(1):30-45.
28. Dignan FL, Amrolia P, Clark A, Cornish J, Jackson G, Mahendra P, Scarisbrick JJ, Taylor PC, **Shaw BE**, Potter MN; on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow Transplantation. Diagnosis and management of chronic graft-versus-host disease. *Br J Haematol.* 2012 Jul;158(1):46-61.
29. Lown RN, **Shaw BE**. Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision. *Bone Marrow Transplant.* 2013 Feb;48(2):210-9.
30. **Bronwen E Shaw#**, Katharina Fleischhauer#, (joint first author), Theodore Gooley., Mari Malkki, Peter Bardy, Jean-Denis Bignon, Valérie Dubois, Mary M. Horowitz, J Alejandro Madrigal, Yasuo Morishima, Machteld Oudshoorn, Olle Ringden, Stephen Spellman, Andrea Velardi, M.D., Elisabetta Zino, B.Sc., Effie W. Petersdorf.. A retrospective study of the impact of T cell epitope matching at HLA-DPB1 in recipients of unrelated donor hematopoietic cell transplantation. *Lancet Oncol.* 2012 Apr;13(4):366-74.
31. Arrieta-Bolaños E, Alejandro Madrigal J, **Shaw BE**. Transforming growth factor- $\beta$ 1 polymorphisms and the outcome of hematopoietic stem cell transplantation. *Int J Immunogenet.* 2012 Jun;39(3):192-202.
32. **Shaw BE**, Confer DL, Hwang WY, Pamphilon DH, Pulsipher MA. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Review. *Haematologica.* 2011 Jul;96(7):942-7.
33. Anoop P, **Shaw BE**, Riley U, Ethell ME, Taj M, Lancaster DL, Atra A, Saso R, Littlewood S, Mohammed K, Davies F, Treleaven J, Morgan GJ, Potter MN. Clinical profile and outcome of urotheliotropic viral haemorrhagic cystitis



following haematopoietic stem cell transplantation: a 7-year tertiary centre analysis. *Hematology*. 2011 Jul;16(4):213-20.

34. Dignan FL, Greenblatt D, Cox M, Cavenagh J, Oakervee H, Apperley JF, Fielding AK, Pagliuca A, Mufti G, Raj K, Marks DI, Amrolia P, Peniket A, Medd P, Potter MN, **Shaw BE**, Scarisbrick JJ. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. *Bone Marrow Transplant*. 2012 Jun;47(6):824-30.
35. **Shaw BE**, Apperley JF, Russell NH, Craddock C, Liakopoulou E, Potter MN, Wynn R, Gibson B, Pearce RM, Kirkland K, Lee J, Madrigal JA, Cook G, Byrne JL. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. *Br J Haematol*. 2011 Mar 8. doi: 10.1111/j.1365-2141.2011.08615.x. [Epub ahead of print]
36. Confer DL, **Shaw BE**, Pamphilon DH. WMDA guidelines for subsequent donations following initial BM or PBSCs. *Bone Marrow Transplant*. 2011 Nov;46(11):1409-12.
37. Mohammed K, Dignan F, Ethell ME, Davies FE, Morgan GJ, Riley U, Evans S, Potter MN, **Shaw BE**. An early computed tomography-guided antifungal treatment strategy is safe and efficacious in patients undergoing chemotherapy for high-risk acute leukemia. *Leuk Lymphoma*. 2011 Feb;52(2):339-40
38. Boo M, van Walraven SM, Chapman J, Lindberg B, Schmidt AH, **Shaw BE**, Switzer GE, Yang E, Egeland T. Remuneration of hematopoietic stem cell donors: principles and perspective of the World Marrow Donor Association. *Blood*. 2011 Jan 6;117(1):21-5. Epub 2010 Oct 4.
39. King RJ, Confer DL, Greinix HT, Halter J, Horowitz M, Schmidt AH, Costeas P, **Shaw B**, Egeland T. Unrelated hematopoietic stem cell donors as research subjects. *Bone Marrow Transplant*. 2011 Jan;46(1):10-3. Epub 2010 Mar 1.
40. Kanga U, McWhinnie AJ, Mourya M, **Shaw BE**, Madrigal JA, Mehra NK. A novel HLA-DPB1 allele, DPB1\*125:01, identified by sequence-based typing in an Indian individual. *Tissue Antigens*. 2011 Jan;77(1):85-7.
41. **Shaw BE**, Arguello R, Garcia-Sepulveda CA, Madrigal JA. The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. *Br J Haematol*. 2010 Aug;150(3):251-8. Epub 2010 Jun 15.

Review.

42. **Shaw BE**. First do no harm. *Blood*. 2010 Jun 17;115(24):4978-9.
43. Duarte RF, **Shaw BE**, Marín P, Kottaridis P, Ortiz M, Morante C, Delgado J, Gayoso J, Goterriz R, Martínez-Chamorro C, Mateos-Mazón JJ, Ramírez C, de la Rubia J, Achtereekte H, Gandhi PJ, Douglas KW, Russell NH. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. *Bone Marrow Transplant*. 2011 Jan;46(1):52-8. Epub 2010 Mar 22.
44. Hiwarkar P, **Shaw BE**, Tredger JM, Brown NW, Kulkarni S, Saso R, Evans S, Treleaven J, Davies FE, Ethell ME, Morgan GJ, Potter MN. Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin. *Clin Transplant*. 2010 Feb 25. [Epub ahead of print]
45. **Shaw BE**, Ball L, Beksac M, Bengtsson M, Confer D, Diler S, Fechter M, Greinix H, Koh M, Lee S, Nicoloso-De-Faveri G, Philippe J, Pollichieni S, Pulsipher M, Schmidt A, Yang E, van Walraven AM; Clinical Working Group; Ethics Working Group of the WMDA. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. *Bone Marrow Transplant*. 2010 May;45(5):832-8. Epub 2010 Feb 22.
46. van Walraven SM, Nicoloso-de Faveri G, Axdorph-Nygell UA, Douglas KW, Jones DA, Lee SJ, Pulsipher M, Ritchie L, Halter J, **Shaw BE**. Family donor care management: principles and recommendations. *Bone Marrow Transplant*. 2010 Aug;45(8):1269-73.
47. **Shaw BE**, Mayor NP, Russell NH, Apperley JF, Clark RE, Cornish J, Darbyshire P, Ethell ME, Goldman JM, Little AM, Mackinnon S, Marks DI, Pagliuca A, Thomson K, Marsh SG, Madrigal JA. Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. *Leukemia*. 2010 Jan;24(1):58-65. Epub 2009 Nov 19.
48. Berro M, Mayor NP, Maldonado-Torres H, Cooke L, Kusminsky G, Marsh SG, Madrigal AA, **Shaw BE**. Association of functional polymorphisms of the transforming growth factor B1 gene with survival and graft-versus-host

- disease after unrelated donor hematopoietic stem cell transplantation. *Haematologica*. 2010 Feb;95(2):276-83. Epub 2009 Aug 27.
49. Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, Liakopoulou E, Fielding AK, Mackinnon S, Olavarria E, Potter MN, Russell NH, **Shaw BE**, Cook G, Goldstone AH, Marks DI. Favorable outcomes with alemtuzumab conditioned unrelated donor stem cell transplantation in adults with high risk Philadelphia chromosome negative acute lymphoblastic leukemia in first complete remission. *Haematologica*. 2009 Oct;94(10):1399-406
50. Querol S, Mufti GJ, Marsh SG, Pagliuca A, Little AM, **Shaw BE**, Jeffery R, Garcia J, Goldman JM, Madrigal JA. Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be? *Haematologica*. 2009 Apr;94(4):536-41.
51. Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, Potter MN, Ethell ME, **Shaw BE**, Morgan GJ. The impact of extramedullary disease at presentation on the outcome of myeloma. *Leuk Lymphoma*. 2009 Feb;50(2):230-5.
52. Tulpule S, **Shaw BE**, Makoni P, Little AM, Madrigal JA, Goldman JM. Severe allergic reaction with anaphylaxis to G-CSF (lenograstim) in a healthy donor. *Bone Marrow Transplant*. 2009 Jul;44(2):129-30.
53. **Shaw BE**, Veys P, Pagliuca A, Addada J, Cook G, Craddock CF, Gennery AR, Goldman J, Mackinnon S, Madrigal JA, Marks DI, Navarrete C, Potter MN, Querol S, Regan F, Russell NH, Hough RE. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms. *Bone Marrow Transplant*. 2009 Jul;44(1):7-12.
54. Dignan FL, Evans SO, Ethell ME, **Shaw BE**, Davies FE, Dearden CE, Treleaven JG, Riley UB, Morgan GJ, Potter MN. An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. *Bone Marrow Transplant*. 2009 Jul;44(1):51-6.
55. **Shaw BE**. The clinical implications of HLA mismatches in unrelated donor haematopoietic cell transplantation. *Int J Immunogenet*. 2008 Aug;35(4-5):367-74.

56. **Shaw BE**, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towilson KE, Apperley JF, Chakraverty R, Craddock CF, Kazmi MA, Littlewood TJ, Milligan DW, Pagliuca A, Thomson KJ, Marks DI, Russell NH. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. *Bone Marrow Transplant.* 2008 Dec;42(12):783-9.
57. Mayor NP, **Shaw BE**, Madrigal JA, Marsh SG. No impact of NOD2/CARD15 on outcome after SCT: a reply. *Bone Marrow Transplant.* 2008 Dec;42(12):837-8.
58. Srikanth M, Davies FE, Wu P, Jenner MW, Ethell ME, Potter MN, **Shaw BE**, Saso RM, Dines S, Morgan GJ. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. *Eur J Haematol.* 2008 Dec;81(6):432-6. Epub 2008 Aug 6.
59. Tholouli E, Liakopoulou E, Greenfield HM, **Shaw BE**, Tauro S, Byrne JL, Dennis M, Burthem J, Lucas GS, Craddock C, Russell NH, Liu Yin JA. Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. *Br J Haematol.* 2008 May 19. [Epub ahead of print]
60. Ingram W, Devereux S, Das-Gupta EP, Russell NH, Haynes AP, Byrne JL, **Shaw BE**, McMillan A, Gonzalez J, Ho A, Mufti GJ, Pagliuca, A. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. *Br J Haematol.* 2008; 141(2): 235-43
61. **Shaw BE**, Russell NH. Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. *Bone Marrow Transplant.* 2008; 41(5): 495-503
62. Mayor NP, **Shaw BE**, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, et al. In reply: NOD2/CARD15 Polymorphisms in Allogeneic Stem-Cell Transplantation From Unrelated Donors: T Depletion Matters. *J Clin Oncol* 2008; 26(2): 339
63. Madrigal A, **Shaw BE**. Immunogenetic factors in donors and patients that affect the outcome of hematopoietic stem cell transplantation. *Blood Cells Mol Dis* 2008;40(1):40-3.

64. Bishton MJ, Lush RJ, Byrne JL, Russell NH, **Shaw BE**, Haynes AP. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. *Br J Haematol* 2007;136(5):752-61.
65. Das-Gupta EP, Russell NH, **Shaw BE**, Pearce RM, Byrne JL. Long-Term Outcome of Unrelated Donor Transplantation for AML Using Myeloablative Conditioning Incorporating Pretransplant Alemtuzumab. *Biol Blood Marrow Transplant* 2007;13(6):724-33.
66. Mayor NP, **Shaw BE**, Keshav S, Madrigal JA, Marsh SG. A novel technique for NOD2/CARD15 genotyping using PCR-SSP. *J Immunol Methods* 2007;327(1-2):82-7.
67. Mayor NP, **Shaw BE**, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, et al. Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. *J Clin Oncol* 2007;25(27):4262-9.
68. **Shaw BE**, Gooley T, Madrigal JA, Malkki M, Marsh SG, Petersdorf EW. Clinical importance of HLA-DPB1 in haematopoietic cell transplantation. *Tissue Antigens* 2007;69 Suppl 1:36-41.
69. **Shaw BE**, Byrne JL, Das-Gupta E, Carter GI, Russell NH. The Impact of Chimerism Patterns and Predonor Leukocyte Infusion Lymphopenia on Survival following T Cell-Depleted Reduced Intensity Conditioned Transplants. *Biol Blood Marrow Transplant* 2007;13(5):550-9.
70. **Shaw BE**, Boswell T, Byrne JL, Yates C, Russell NH. Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. *Bone Marrow Transplant* 2007;39(10):623-9.
71. **Shaw BE**. Practical hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2007;40(5):503.
72. **Shaw BE**, Gooley TA, Malkki M, Madrigal JA, Begovich AB, Horowitz MM, et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. *Blood* 2007;110(13):4560-6.
73. Duarte RF, Pamphilon D, Cornish J, **Shaw BE**, Samson D, Craddock C, et al. Topical issues in unrelated donor haematopoietic stem cell transplants: a

- report from a workshop convened by the Anthony Nolan Trust in London - 2005. *Bone Marrow Transplant* 2006;37(10):901-8.
74. **Shaw BE**, Marsh SG, Mayor NP, Russell NH, Madrigal JA. HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. *Blood* 2006;107(3):1220-6.
75. Duarte RF, Delgado J, **Shaw BE**, Wrench DJ, Ethell M, Patch D, et al. Histologic features of the liver biopsy predict the clinical outcome for patients with graft-versus-host disease of the liver. *Biol Blood Marrow Transplant* 2005;11(10):805-13.
76. Kroger N, **Shaw B**, Iacobelli S, Zabelina T, Peggs K, Shimoni A, et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. *Br J Haematol* 2005;129(5):631-43.
77. Mayor NP, Cox ST, McWhinnie AJ, Arguello JR, **Shaw BE**, Little AM, et al. Sequence of a novel HLA-A\*0301 intronic variant (A\*03010103). *Tissue Antigens* 2005;65(1):107-9.
78. **Shaw BE**, Russell NH, Devereux S, Das-Gupta E, Mackinnon S, Madrigal JA, et al. The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors. *Haematologica* 2005;90(11):1562-9.
79. **Shaw BE**, Maldonado H, Madrigal JA, Smith C, Petronzelli F, Mayor NP, et al. Polymorphisms in the TNFA gene promoter region show evidence of strong linkage disequilibrium with HLA and are associated with delayed neutrophil engraftment in unrelated donor hematopoietic stem cell transplantation. *Tissue Antigens* 2004;63(5):401-11.
80. **Shaw BE**, Barber LD, Madrigal JA, Cleaver S, Marsh SG. Scoring for HLA matching? A clinical test of HistoCheck. *Bone Marrow Transplant* 2004;34(4):367-8.
81. Madrigal JA, Garcia CA, Gutierrez M, **Shaw BE**, Arguello R, Little A-M, et al. El complejo mayor de histocompatibilidad y su papel biologica. HLA y su papel en la evolucion clinica de trasplantes y enfermedades autoinmunes. *Hematologia* 2003;6(4):1-8.

82. **Shaw BE**, Potter MN, Mayor NP, Pay AL, Smith C, Goldman JM, et al. The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation. *Bone Marrow Transplant* 2003;31(11):1001-8.
83. **Shaw BE**, Peggs K, Bird JM, Cavenagh J, Hunter A, Alejandro Madrigal J, et al. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. *Br J Haematol* 2003;123(5):886-895.
84. **Shaw B**, Mehta AB. Pancytopenia responding to treatment of hyperthyroidism: a clinical case and review of the literature. *Clin Lab Haematol* 2002;24(6):385-7.
85. **Shaw BE**, Perry D, Hoffbrand AV. Progressive arterial thrombosis in a patient with non-Hodgkin's lymphoma, a lupus anticoagulant, factor V Leiden mutation and paraprotein, following chemotherapy. *Leuk Lymphoma* 2001;42(1-2):221-3.
86. **Shaw BE**, Madrigal JA, Potter M. Improving the outcome of unrelated donor stem cell transplantation by molecular matching. *Blood Rev* 2001;15(4):167-74.
87. Chopra R, Eaton JD, Grassi A, Potter M, **Shaw B**, Salat C, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. *Br J Haematol* 2000;111(4):1122-9.
88. Paterson PJ, Marshall SR, **Shaw B**, Kendra JR, Ethel M, Kibbler CC, et al. Fatal invasive cerebral *Absidia corymbifera* infection following bone marrow transplantation. *Bone Marrow Transplant* 2000;26(6):701-3.
89. Somers LJ, **Shaw B**, Lyn BE, McMillan AM, Mahendra P. Meningeal myeloma in the absence of systemic disease, and as the initial feature of disease progression. *Clin Lab Haematol* 1998;20(3):189-90.

### Workshop Proceedings

- 1 Bronwen E Shaw and Michael D Varney on behalf of participating laboratories. Haemopoetic Stem cell Component- HLA-DPB1 joint report. In: Immunobiology of the Human MHC. Proceedings of the 13<sup>th</sup> International Histocompatibility Workshop and Conference. Hansen J, Ed. Seattle: IHWG Press. 2007

- 2 Bronwen E Shaw, Steven G E Marsh, J Alejandro Madrigal. Role of HLA matching in unrelated donor transplant – An update of the Anthony Nolan data. In: Immunobiology of the Human MHC. Proceedings of the 13<sup>th</sup> International Histocompatibility Workshop and Conference. Hansen J, Ed. Seattle: IHWG Press. 2007
- 3 B. E. Shaw, M. N. Potter, H. Grant Prentice, N. Mayor, A. L. Pay, S. G. E. Marsh and J. A. Madrigal. Graft versus host disease in matched T cell depleted unrelated donor haematopoietic stem cell transplants . In: Immunobiology of the Human MHC. Proceedings of the 13<sup>th</sup> International Histocompatibility Workshop and Conference. Hansen J, Ed. Seattle: IHWG Press. 2007
- 4 B.E. Shaw, M.N. Potter, H. Grant Prentice, N. Mayor, A.L. Pay, P. Travers, S. G. E. Marsh and J.A. Madrigal. Disease relapse following volunteer donor haematopoietic stem cell transplantation. In: Immunobiology of the Human MHC. Proceedings of the 13<sup>th</sup> International Histocompatibility Workshop and Conference. Hansen J, Ed. Seattle: IHWG Press. 2007

## **Internet**

Regular contributions to the Medical Masterclass website of MCQs.

Haematology MCQs prepared for MRCP I in the form of a CD rom for Blackwell Science Limited. Now included in Medical Masterclass website/paper modules.



## Presentations as an invited speaker

- Mar 2014 Donor Issues  
EBMT, Milan
- Nov 2013 What do we know and what should we do about GI toxicity after stem cell transplantation: the role of the gut in GvHD  
GI and nutritional consequences of cancer treatment, London
- Nov 2013 Second allogeneic transplants  
BSBMT Education Day, London
- Oct 2013 Donor safety and suitability for transplantation  
WBMT/WHO meeting, Brazil
- Sept 2013 Donor selection for transplantation  
UCT Bone Marrow Transplant Seminar, Cape Town
- Sept 2013 Donor care and management  
South African Bone Marrow Donor Registry 21<sup>st</sup> Anniversary meeting, Cape Town
- June 2013 Donor Safety and Donor Selection Criteria  
NMDP Board Meeting, Las Vegas
- June 2013 DPB1 T-Cell Epitope Matching in HSC Transplant  
Georgetown Lecture Series, Live Online
- April 2013 Are our increasing demands on donors justifiable?  
EBMT, London
- Oct 2012 Biosimilars in paediatric practice  
Paediatric symposium, London
- Oct 2012 The use of biosimilars in haematology  
EBMT nurses group, London
- Sept 2012 Unrelated donors versus saviour siblings: debate  
Science Festival, Aberdeen
- May 2012 Adverse events reporting  
IDRC, Sydney
- April 2012 The best donor for transplantation.  
ESH-EBMT training course, Sofia
- April 2012 The safety of G-CSF in healthy donors  
CHUGAI CORPORATE SYMPOSIUM  
EBMT, Geneva

- April 2012 A retrospective study of the impact of T cell epitope matching at HLA-DPB1 in recipients of unrelated donor hematopoietic cell transplant  
IMMUNOBIOLOGY WORKING GROUP  
EBMT, Geneva
- April 2012 Impact of stem cell source comparison between peripheral blood and bone marrow: Donor side  
Joint WMDA/EBMT session  
EBMT, Geneva
- Mar 2012 HSCT: The experiences of registries and future needs  
LEGAL AND ETHICAL CHALLENGES IN HSCT, Basel
- Feb 2012 Optimising unrelated donor selection: Development of GIAS  
SYMPOSIUM ON ALTERNATIVE DONOR TRANSPLANTATION: THE STATE OF THE ART, London
- June 2011 Donor selection strategies  
Southampton and Leeds
- May 2011 The best donor for transplantation.  
ESH-EBMT training course, La Baule
- Apr 2011 Chronic GvHD: prevention, treatment options and outcomes  
THERAKOS corporate symposium  
EBMT, Paris
- Feb 2011 Vigilance and Surveillance in haematopoietic stem cell transplantation.  
NOTIFY project meeting, Bologna
- Nov 2010 Alternative Donor Transplantation: historical and future perspective  
Taiwanese Society of Haematology, Taiwan  
Guangzhou, China
- Aug 2010 The Role Of HLA-DPB1 In The Outcome Of Unrelated Donor Hematopoietic Stem Cell Transplantation  
Donor selection for transplantation  
Disease Relapse Post transplantation  
25<sup>th</sup> CURRENT COURSE ON MOLECULAR GENETICS, ASHI, Mexico City
- June 2010 Advances in transplantation  
HAEMATOLOGICAL MALIGNANCIES, London
- June 2010 GCSF in normal donors  
GCSF symposium, Barcelona
- Oct 2009 Graft Identification Advisory Service (GIAS)  
JOINT SYMPOSIUM ON CORD BLOOD TRANSPLANTATION - FUTURE CHALLENGES, London
- June 2009 Alternative donors and cord blood transplantation

HAEMATOLOGICAL MALIGNANCIES, London

- Oct 2008 Understanding HLA and donor selection strategies  
BSBMT EDUCATIONAL DAY, London
- Aug 2008 The Role Of HLA-DPB1 In The Outcome Of Unrelated Donor  
Hematopoietic Stem Cell Transplantation  
The Reduced Intensity conditioning-indications, implications and  
outcomes  
Donor Lymphocytes Infusions, Second Transplants And Other Options  
For Preventing And Treating Disease Relapse Post transplantation  
23<sup>th</sup> CURRENT COURSE ON MOLECULAR GENETICS, ASHI, Mexico  
City
- May 2008 GvHD/GvL  
BSHI SPRING TRAINING DAY, Birmingham
- April 2008 Finding a donor for stem cell transplantation: registries, regulations and  
outcomes  
EDUCATIONAL DAY, PRINCESS OF WALES HOSPITAL, Wales
- Mar 2007 Factors impacting on the success of DLI in recipients of reduced  
intensity conditioned transplants  
IMMUNOBIOLOGY WORKING PARTY, EBMT, Lyon
- Feb 2006 Major Histocompatibility antigens: the clinical impact of HLA  
mismatches and donor selection strategies  
IMMUNOGENETICS IN HAEMATOLOGY AND STEM CELL  
TRANSPLANTATION, Polish Society of Immunogenetics, Wroclaw,  
Poland
- June 2005 The Anthony Nolan Experience, outcome data on 423 transplant pairs  
and donor selection algorithms  
TOPICAL ISSUES IN UNRELATED DONOR HAEMATOPOIETIC  
STEM CELL TRANSPLANTS: a workshop convened by the Anthony  
Nolan trust, London
- March 2005 The impact of HLA-DPB1 antigen and allele mismatches in unrelated  
donor HCT  
IMMUNOBIOLOGY WORKING PARTY, EBMT, Prague
- July 2003 Potential immunosuppressive effects of CMV in unrelated stem cell  
transplantation.  
IMMUNOBIOLOGY WORKING PARTY, EBMT, Turkey
- Jan 2003 Mismatches and more mismatches  
CURRENT ISSUES IN HAEMATOPOIETIC STEM CELL  
TRANSPLANTATION, Royal Free Hospital, London

## First author abstracts accepted for presentation

- Dec 1999 **Oral presentation at the ASH, New Orleans:**  
The use of Defibrotide in the management of vascular endothelial complications (VOD/HUS/TTP) of stem cell transplantation.  
B E Shaw, M N Potter, R Pawson, A E Virchis, D Patch, K Murphy, D Perry and H G Prentice.
- Dec 2000 **Poster presentation at the ASH, San Francisco:**  
The genetic factors which affect the outcome of unrelated bone marrow transplantation  
J. Alejandro Madrigal, Bronwen E Shaw, Paul Brookes, Mike Potter, H. Grant Prentice, John M Goldman, Ann-Margaret Little, Paul J Travers, Andrea L. Pay.
- April 2001 **Oral presentation at the BSH, Harrogate**  
Sept 2001 **Oral presentation at the British Society of Histocompatibility and Immunogenetics, Cambridge**  
Matching for HLA DPB1 increases the survival in unrelated stem cell transplants, however is associated with an increased relapse rate.  
Bronwen E Shaw, Andrea L Pay, H Grant Prentice, Mike N Potter, Paul Brookes, John M Goldman, Ann-Margaret Little, Paul J Travers, Steven Marsh and J Alejandro Madrigal.
- Dec 2001 **Poster presentation at ASH, Orlando**  
High Resolution Molecular Typing to ensure Allele Level Matching for Six Highly Polymorphic HLA Antigens increases the Overall Survival in Volunteer Donor Stem Cell Transplantation, however "Perfect" matches are found in only 10% of Pairs  
Bronwen E Shaw, Andrea L Pay, Neema Mayor, Michael N Potter, H Grant Prentice, John M Goldman, James Robinson, Steven Marsh and J Alejandro Madrigal.
- March 2002 **Oral Presentations at the EBMT, Montreux**  
HLA-DPB1 plays a role in the outcome of unrelated stem cell transplants in pairs completely matched at the other five transplantation loci  
Bronwen.E Shaw, A.L.Pay, M.N.Potter, N. Mayor, H. Grant Prentice, A.M.Little, S.G.E.Marsh and J.A.Madrigal  
  
The presence of mild acute graft versus host disease in a T cell depleted unrelated donor transplant setting improves overall survival  
B.E Shaw, A.L.Pay, M.N.Potter, H. Grant Prentice, N. Mayor, S.G.E.Marsh and J.A.Madrigal  
  
**Poster Presentation at the EBMT, Montreux**  
The importance of patient and donor CMV status in unrelated stem cell transplantation  
B.E Shaw, A.L.Pay, M.N.Potter, P.Travers, N. Mayor, H. Grant Prentice, S.G.E.Marsh and J.A.Madrigal

- May 2002 **Oral Presentation at the 13<sup>th</sup> International Histocompatibility Workshop, Victoria**  
 Role of HLA matching in unrelated donor transplant – An update of the Anthony Nolan data.
- Poster Presentations at the 13<sup>th</sup> International Histocompatibility Conference, Seattle**  
 Graft versus host disease in matched T cell depleted unrelated donor haematopoietic stem cell transplants  
 B. E. Shaw, M. N. Potter, H. Grant Prentice, N. Mayor, A. L. Pay, S. G. E. Marsh and J. A. Madrigal  
 Disease relapse following volunteer donor haematopoietic stem cell transplantation  
 B. E. Shaw, M. N. Potter, H. Grant Prentice, N. Mayor, A. L. Pay, P. Travers, S. G. E. Marsh and J. A. Madrigal  
 Donor age is not a significant factor affecting overall survival in HLA matched unrelated donor stem cell transplants.  
 B.E Shaw, S.G.E.Marsh , N. Mayor, H.Grant Prentice, A.L.Pay, A-M. Little, M.N.Potter and J.A.Madrigal
- Sept 2002 **Oral presentation for the Promega young scientist of the year award, British Society of Histocompatibility and Immunogenetics, Glasgow**  
 The importance of CMV status in unrelated haematopoietic stem cell transplantation  
 B.E. Shaw, M.N. Potter, P. Travers, N.P. Mayor, H. Grant Prentice, S.G.E. Marsh and J.A. Madrigal
- July 2003 **Oral Presentations at the EBMT, Istanbul**  
 TNF alpha promoter polymorphisms have a significant impact on engraftment in unrelated donor haematopoietic stem cell transplant  
 Bronwen E Shaw, Colette Smith, Michael N Potter, Neema P Mayor, Steven G E Marsh and J Alejandro Madrigal
- Poster Presentation at the EBMT, Istanbul**  
 Unrelated donor haematopoietic stem cell transplantation (UD-SCT) for multiple myeloma (MM): a retrospective study by the Clinical Trials committee of the British Society of BMT (BSBMT) and the Anthony Nolan Trust (ANT)  
 Bronwen E Shaw, Keiran Towlson, Jennifer M Bird, J. Alejandro Madrigal, Jamie Cavenagh, David I Marks
- Dec 2004 **Oral presentations at the ASH, San Diego:**  
 Matching status at amino acid positions 57 and 65 of the HLA–DPB1 beta chain determines outcome in recipients of Unrelated Donor Haematopoietic Stem Cell Transplants  
 Bronwen E Shaw, Steven G E Marsh, Neema P Mayor, J Alejandro Madrigal
- Increased disease relapse in HLA–DPB1 matched recipients of Unrelated Donor Transplants is not confined to pairs matched for the other five HLA loci

Bronwen E Shaw, Steven G E Marsh, Neema P Mayor, J Alejandro Madrigal

March 2005 **Poster Presentations at the EBMT, Prague**

The use of HLA mismatched, bone marrow derived Haematopoietic Stem Cells is significantly associated with primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors

Bronwen E Shaw, M Gilyead, Emma Das-Gupta, Jennifer L Byrne, Nigel H Russell

HLA-DPB1 specific responses between unrelated individuals can be demonstrated by the production of interferon gamma in an ELISpot assay

Bronwen E Shaw, Linda D Barber, Neema P Mayor, Steven GE Marsh, J Alejandro Madrigal

Apr 2005 **Oral presentations at the BSH, Manchester:**

Donor factors are significantly associated with primary non-engraftment in recipients of reduced intensity conditioned (RIC) transplants from unrelated donors

Bronwen E Shaw, M Gilyead, Emma Das-Gupta, J Alejandro Madrigal, Jennifer L Byrne, Nigel H Russell

May 2005 **Oral presentations at the BSBMT educational day, London:**

The impact of HLA Class I mismatching on the outcome of unrelated donor Haematopoietic Stem Cell Transplantation – is it possible to choose between mismatched donors?

Bronwen E Shaw, Steven G E Marsh, Neema P Mayor, J Alejandro Madrigal

Dec 2005 **Poster presentations at the ASH, Atlanta:**

Single HLA allele mismatches are well tolerated in the recipients of T cell depleted reduced intensity conditioned transplants from unrelated donors

Bronwen E Shaw, Nigel H Russell, Steve Devereux, Emma Das-Gupta, Stephen Mackinnon, J Alejandro Madrigal, Anthony Pagliuca, Ghulam J Mufti, Jennifer L Byrne

Converting mixed chimerism to full donor chimerism in recipients of Campath-containing reduced intensity transplants reduces the relapse risk and results in significantly improved survival compared to those with persistent full donor chimerism

Bronwen E Shaw, Jenny L Byrne, Emma Das-Gupta, Ian Carter, Nigel H Russell

Mar 2006 **Poster presentations at the EBMT, Hamburg:**

Converting mixed chimerism to full donor chimerism in recipients of Campath-containing reduced intensity transplants reduces the relapse risk and results in significantly improved survival compared to those with persistent full donor chimerism

Bronwen E Shaw, Jenny L Byrne, Emma Das-Gupta, Ian Carter, Nigel H Russell

An MRSA outbreak in a stem cell transplant unit: analysis before and after a highly effective eradication strategy

Bronwen E Shaw, Tim Boswell, Jennifer L Byrne, Carl Yates, Nigel H Russell

May 2006

**Oral presentation at the BSBMT Scientific Day, London:**

Functional donor leukocyte infusion (DLI) responses in recipients of reduced intensity transplants are dependant both on the presence of mixed chimerism and low pre-DLI lymphocyte counts

Bronwen E Shaw, Jenny L Byrne, Emma Das-Gupta, Ian Carter, Nigel H Russell

Dec 2006

**Oral presentations at the ASH, Orlando:**

Low pre-DLI lymphocytes counts are predictive of good disease responses in patients with mixed chimerism following Campath-containing reduced intensity transplants

Bronwen E Shaw, Jenny L Byrne, Emma Das-Gupta, Ian Carter, Nigel H Russell

**Poster presentations at ASH, Orlando:**

Outcome of Second Allogeneic Transplants using Reduced Intensity Conditioning following Relapse after an Initial Allogeneic Transplant  
B E Shaw, G J Mufti, S Mackinnon, J Cavenagh, K Towlson, R Pearce, A Pagliuca, J Apperley, C Craddock, M Kazmi, T Littlewood, D Milligan, D Marks, N H Russell on behalf of the CTC for the British Society for Blood and Marrow Transplantation

Mar 2007

**Oral presentation at EBMT, Lyon**

Outcome of second allogeneic transplants using reduced intensity conditioning following relapse after an initial allogeneic transplant

B E Shaw, G J Mufti, S Mackinnon, J Cavenagh, K Towlson, R Pearce, A Pagliuca, J Apperley, C Craddock, M Kazmi, T Littlewood, D Milligan, K Thomson, D Marks, N H Russell on behalf of the CTC for the British Society for Blood and Marrow Transplantation

July 2007

**Oral presentation at the GvH/GvL ESH meeting, Sitges**

The importance of HLA-DPB1 in unrelated donor haematopoietic cell transplantation

Bronwen E Shaw, Ted Gooley, Mari Malkki, J Alejandro Madrigal, Ann B Begovich, Mary M Horowitz, Alois Gratwohl, Olle Ringdén, Steven GE Marsh and Effie W Petersdorf

Dec 2007

**Oral presentations at the ASH, Atlanta:**

A comparison of stem cell source in recipients of T-cell depleted myeloablative transplants for leukaemia: no difference in mortality using BM or PBSC

B E Shaw, N H Russell, T Pagliuca, J Apperley, G Cook, S Mackinnon, J A Madrigal, D Marks, G J Morgan, K Peggs, M Potter, K Towlson, J L Byrne

**Poster presentations at ASH, Orlando:**

Matching for 12 HLA alleles is associated with a significantly superior survival due to a lower mortality in recipients of unrelated donor haematopoietic cell transplants for early but not late stage leukaemia

B E Shaw, N P Mayor, A-M Little, N H Russell, T Pagliuca, M Ethell, G J Morgan, J A Madrigal, S G E Marsh

Mar 2008

**Oral presentation at EBMT, Florence:**

Survival in patients receiving a transplant from an HLA- mismatched donor (at 10/10 alleles) can be significantly improved by selecting a donor mismatched for HLA-DPB1

B. Shaw, N. Mayor, A.M. Little, N. Russell, A. Pagliuca, M. Ethell, G. Morgan, J.A. Madrigal, S. Marsh

**Poster presentation at EBMT, Florence:**

No impact on survival is seen when comparing the use of BM or PBSC as the stem cell source in recipients of T-cell depleted myeloablative transplants for leukaemia and MDS

B. Shaw, N. Russell, A. Pagliuca, J. Apperley, G. Cook, S. Mackinnon, J. Madrigal, D. Marks, G. Morgan, R. Pearce, K. Peggs, M. Potter, K. Towlson, J. Byrne

Sept 2008

**Oral presentation at the 15<sup>th</sup> International Histocompatibility Workshop, Rio de Janeiro**

Diverging effects of HLA-DPB1 matching status on outcome following UD transplantation is dependent upon disease stage and matching for other HLA alleles",

Bronwen Shaw, Neema Mayor, Ann-Margaret Little, Nigel Russell, Mark Ethell, Mike Potter, J Alejandro Madrigal, Steven G E Marsh

Mar 2009

**Oral presentation at EBMT, Gothenburg:**

Significant differences in outcome following unrelated donor HCT can be better predicted using an algorithm incorporating both allele and epitope level matching for HLA-DPB1 From the International Histocompatibility Working Group in Hematopoietic Cell Transplantation

B.E. Shaw, K. Fleischhauer, E. Zino, M. Malkki, S. Spellman, Y. Morishima, T. Gooley, E. Petersdorf

Dec 2009

**Poster presentations at ASH, New Orleans:**



A comparison of stem cell source in adult and paediatric recipients of T-cell depleted myeloablative transplants for standard risk leukaemia: no difference in mortality using BM or PBSC

B E Shaw, J Apperley, N H Russell, C Craddock, E Liakopoulou, M N Potter, R Wynn, B Gibson, R Pearce, K Kirkland, J A Madrigal, G Cook, J L Byrne

Dec 2010

**Oral presentations at ASH, Atlanta:**

Permissive HLA-DPB1 mismatching compared to a non-permissive mismatching significantly improves overall survival following allogeneic transplantation in patients with both 10/10 and 9/10 matched unrelated donors

B E Shaw, K Fleischhauer, M Malkki, T Gooley, E Zino, S Spellman, Y Morishima, A Velardi, P Bardy, J Bignon, J A Madrigal, E W Petersdorf

**Poster presentations at ASH, Atlanta:**

Results of a prospective clinical trial of pre-DLI lymphoreduction using oral fludarabine in patients with mixed chimerism post allogeneic transplant

Bronwen E Shaw, Jennifer L Byrne, Emma Das-Gupta, Mark E Ethell, Daniel Figueroa, J Alejandro Madrigal, Gareth J Morgan, Sameer Tulpule, Michael N Potter, Nigel H Russell

Mar 2011

**Poster presentations at EBMT, Paris**

Results of a prospective clinical trial of pre-DLI lymphoreduction using oral fludarabine in patients with mixed chimerism post allogeneic transplant

Bronwen E Shaw, Jennifer L Byrne, Emma Das-Gupta, Mark E Ethell, Daniel Figueroa, J Alejandro Madrigal, Gareth J Morgan, Sameer Tulpule, Michael N Potter, Nigel H Russell